Filing Summary
Issuer identified in filing: NLS Pharmaceutics Ltd., not Newcelx Ltd. The Form 6-K covers December 2021 and was signed on December 14, 2021. The issuer reports under Form 20-F.
Business Context and Reporting Period
On December 10, 2021, NLS Pharmaceutics convened an extraordinary shareholders’ meeting. A quorum was present, and shareholders approved all agenda items as proposed.
Corporate and Capital Structure Changes
- The company filed amended and restated articles of association with the commercial registry of the Canton of Zurich.
- The registered seat was transferred from Stans, Nidwalden, to Kloten, Zurich.
- The company’s address was changed to The Circle 6, Postfach, 8058 Zurich, Switzerland.
- Authorized share capital was increased, through December 10, 2023, to a maximum of CHF 147,485.36, corresponding to up to 7,374,268 registered shares.
- Conditional share capital for employee and advisory options was increased to a maximum of CHF 42,182, corresponding to up to 2,109,100 registered shares.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes, Outlook, and Risks
The principal disclosed changes are the relocation of the registered seat and the increases in authorized and conditional share capital. The filing does not provide management guidance, operating outlook, financial forecasts, contingencies, or discussion of unusual items or material business risks.
Key Facts to Verify
- Confirm that the intended issuer is NLS Pharmaceutics Ltd., because the request metadata identifies Newcelx Ltd.
- Review Exhibit 3.1, the amended and restated articles of association, for the detailed capital authorization terms.
- Assess potential future dilution from the authorized issuance of up to 7,374,268 shares and employee or adviser options covering up to 2,109,100 shares.
- Confirm the effective corporate domicile and registered address in Swiss commercial registry records.